Advances in liquid biopsy–based markers in NSCLC
Xiao-Dong Ren,Ning Su,Xian-Ge Sun,Wen-Man Li,Jin Li,Bo-Wen Li,Ruo-Xu Li,Jing Lv,Qian-Ying Xu,Wei-Long Kong,Qing Huang
DOI: https://doi.org/10.1016/bs.acc.2023.02.004
IF: 6.303
2023-03-23
Advances in Clinical Chemistry
Abstract:Lung cancer is the second most–frequently occurring cancer and the leading cause of cancer–associated deaths worldwide. Non–small cell lung cancer (NSCLC), the most common type of lung cancer is often diagnosed in middle or advanced stages and have poor prognosis. Diagnosis of disease at an early stage is a key factor for improving prognosis and reducing mortality, whereas, the currently used diagnostic tools are not sufficiently sensitive for early–stage NSCLC. The emergence of liquid biopsy has ushered in a new era of diagnosis and management of cancers, including NSCLC, since analysis of circulating tumor–derived components, such as cell–free DNA (cfDNA), circulating tumor cells (CTCs), cell–free RNAs (cfRNAs), exosomes, tumor–educated platelets (TEPs), proteins, and metabolites in blood or other biofluids can enable early cancer detection, treatment selection, therapy monitoring and prognosis assessment. There have been great advances in liquid biopsy of NSCLC in the past few years. Hence, this chapter introduces the latest advances on the clinical application of cfDNA, CTCs, cfRNAs and exosomes, with a particular focus on their application as early markers in the diagnosis, treatment and prognosis of NSCLC.
medical laboratory technology